Gain-of-function mutations in the SCN9A gene, which codes for NaV1.7, are linked to severe pain conditions such as primary erythromelalgia, whereas loss-of-function mutations lead to a congenital inability to experience pain. Here, SCN9A is linked to primary erythermalgia.